Drug design, development and therapy··PMID: 41710577
Parang K, Do T, Dinh C, Davani-Davari D, Foroughi M, Khong T et al.
Peptide-drug conjugates (PDCs) are modular, targeted therapeutics composed of a homing peptide linked to a cytotoxic or modulating drug payload via a cleavable/non-cleavable linker. PDCs utilize peptide targeting to enhance the delivery of potent drugs to tumors, providing advantages such as supe...
European journal of nuclear medicine and molecular imaging··PMID: 41699279
Degryse L, Teles L, De Vleeschouwer S, Boeckxstaens L, Jentjens S, Deckers W et al.
This study aims to evaluate differences in PET/CT imaging of meningioma using both gallium-68- and fluorine-18-labelled somatostatin receptor (SSTR) tracers, to characterize incidentally detected meningiomas on SSTR PET/CT, and to analyse institutional experience with Peptide Receptor Radionuclid...
Altus LM, Forster JC, Mercurio J, Kitchener M, Corsini N, Nenke M et al.
The aim of this study was to audit clinical and patient-reported outcomes of patients treated with [177Lu]-DOTA-octreotate (177Lu-DOTATATE) at a single Australian centre over an 11-year period.A retrospective analysis of 189 patients with metastatic or locally advanced neuroendocrine neoplasms or...
Endocrinology, diabetes & metabolism case reports··PMID: 41614693
Chakraborty AM, Ghosh J, Das L, Kumar R, Nahar U, Chatterjee D et al.
Medullary thyroid carcinoma (MTC) constitutes 5-10% of thyroid malignancies but accounts for 15% of thyroid cancer-related mortality. Twenty percent of MTC are hereditary and are part of familial MTC or multiple endocrine neoplasia (MEN) syndromes. Classical MTC presents as a nodular goiter with ...
Schütze C, Borowski M, Freesmeyer M, Freudenberg R, Hänscheid H, Kurth J et al.
The study investigated routinely used radiopharmaceuticals containing lutetium-177 (177Lu), providing reference values for their effective half-life (T1/2,eff). So far, no guidelines regarding discharging this patients exist, are essential to ensure radiation protection of the public. This study ...
Clinical cancer research : an official journal of the American Association for Cancer Research··PMID: 41591997
Becx MN, Hofland J, Krenning EP, Wyld DK, Nonnekens J, Verburg FA et al.
Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-[DOTA0,Tyr3]octreotate (177Lu-Dotatate) is an effective and safe treatment for patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP NET). While 177Lu-Dotatate prolongs progression-free survival (PFS) and preserves q...
Minamimoto R, Kato K, Iwano S, Nishii R, Abe Y, Naganawa S et al.
Neuroendocrine tumors (NETs) are a heterogenous group of neoplasms originating from neuroendocrine cells, most frequently found in the gastrointestinal tract and pancreas. A defining feature of NETs is the overexpression of somatostatin receptors (SSTRs), particularly subtype 2 (SSTR2), which is ...
Current treatment options in oncology··PMID: 41543636
Mohindroo C, Ramirez RA
Peptide receptor radionuclide therapy (PRRT) has become an established treatment for patients with well-differentiated gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) that express somatostatin receptors. Among the available agents, lutetium-177 DOTATATE is the most commonly used radiol...
Shimizu H, Furuya Y, Asai T, Iwama I, Tachibana H, Ishiguro Y et al.
177Lu-DOTATATE-targeted radionuclide therapy (TRT) is effective for patients with somatostatin receptor (SSTR)-positive neuroendocrine tumors; however, radiation safety regulations often necessitate hospitalization, particularly in countries with stringent discharge criteria. This study aimed to ...
Bando T, Otsuka H, Otani T, Kasai R, Otomi Y, Nagao S et al.
To assess therapeutic response in patients with neuroendocrine tumors (NETs) using quantitative post-therapy 177Lu-DOTATATE SPECT/CT metrics, such as standardized uptake values (SUVs), metabolic tumor volume (MTV), and total Lutetium uptake (TLuU), and to propose a response classification system ...
To assess the prognostic impact of pre-treatment circulating other cells on treatment response and survival in neuroendocrine tumor (NET) patients receiving Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE.Healthy donors (HDs, n = 81) and NET patients (n =...
PRRT showed promising potential in the management of patients with pNETs. However, there is still a lack of evidence on its relative efficacy and safety compared with other treatment options. This review aims to synthesize the existing evidence on the efficacy and safety of PRRT (without SSA in k...
Radiological physics and technology··PMID: 41364156
Miyaji N, Miwa K, Yamashita K, Yamashita Y, Ukon N, Ogawa M et al.
Dosimetry using SPECT/CT images enables personalized medicine by estimating absorbed doses and optimizing therapy. Differences in organ contouring and calculation algorithms contribute to inter-institutional variability, emphasizing the need for standardization. The present study aimed to investi...
Intravenous peptide receptor radionuclide therapy (IV-PRRT) has established its role in the treatment algorithm of somatostatin receptor (SSTR)-expressing neuroendocrine neoplasms (NENs). This study aims to evaluate the safety and efficacy of intra-arterial PRRT (IA-PRRT) in patients with SSTR-ex...
Journal of nuclear medicine technology··PMID: 41344824
West V, Morse P, Nguyen M, Ali R, Mallak N, Winters C et al.
Theranostic programs are expanding rapidly, creating a growing need to understand how institutions implement [177Lu]Lu-DOTATATE therapy and [177Lu]Lu-PSMA-617 therapy in clinical practice. Methods: We distributed a 25-question online survey to U.S. health care institutions that administer 177Lu t...
As a novel targeted therapeutic approach, peptide-drug conjugates (PDCs) integrate peptides, drug payloads, and linkers to establish an efficient drug delivery system. In addition to retaining the selective advantage inherent in targeted therapy, this modular approach confers a spectrum of therap...
In 2018, the Food and Drug Administration (FDA) approved lutetium-177 (177Lu) DOTATATE (LUTATHERA, Advanced Accelerator Applications [Novartis]) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Since then, 177Lu DOTATATE has been increas...
Peptide receptor radionuclide therapy (PRRT) has emerged as a promising treatment for metastatic pheochromocytoma and paraganglioma (mPPGL). This study aimed to evaluate PRRT outcomes in patients with mPPGL in a single institution. Methods: Records of patients with mPPGL who received PRRT were re...
We present a high-grade well-differentiated NET with large lesions that demonstrated both SSTR and [18F]F-FDG avidity on baseline PET/CT, an outstanding response following 177Lu-DOTATATE-PRRT with complete resolution of SSTR and [18F]F-FDG uptake, and significant size reduction of liver lesions. ...
Disclaimer: This page aggregates research from PubMed for educational purposes only. Inclusion of a study does not imply endorsement of its findings. Always consult a qualified healthcare professional before making decisions based on research literature.
